Amantadine use in the French prospective NS-Park cohort.

Amantadine Motor complications NS-Park Parkinson’s disease

Journal

Journal of neural transmission (Vienna, Austria : 1996)

ISSN: 1435-1463

Titre abrégé: J Neural Transm (Vienna)

Pays: Austria

ID NLM: 9702341

Informations de publication

Date de publication:
05 Apr 2024

Historique:

received: 15 02 2024

accepted: 25 03 2024

medline: 5 4 2024

pubmed: 5 4 2024

entrez: 5 4 2024

Statut: aheadofprint

Résumé

To assess amantadine use and associated factors in the patients with Parkinson's disease (PD). Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres. Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis). Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users. About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.

Sections du résumé

OBJECTIVE OBJECTIVE

To assess amantadine use and associated factors in the patients with Parkinson's disease (PD).

BACKGROUND BACKGROUND

Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres.

METHODS METHODS

Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis).

RESULTS RESULTS

Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users.

CONCLUSIONS CONCLUSIONS

About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.

Identifiants

DOI: 10.1007/s00702-024-02772-4 PMID: 38578434

pubmed: 38578434

doi: 10.1007/s00702-024-02772-4

pii: 10.1007/s00702-024-02772-4

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Investigateurs

Mickael Aubignat (M)

Eloi Magnin (E)

Pr Pierre Burbaud (PP)

Pr Dominique Guehl (PD)

Alexandra Foubert-Samier (A)

Brice Laurens (B)

Thomas Boraud (T)

Sylvain Vergnet (S)

David Bendetowicz (D)

Thomas Palpacuer (T)

Bérengère Debilly (B)

Philippe Derost (P)

Charlotte Beal (C)

Hayet Salhi (H)

Alice Dormeuil (A)

Aimée Petit (A)

Alban Gravier (A)

Gwendoline Dupont (G)

Lucie Garnier (L)

Valérie Fraix (V)

Anna Castrioto (A)

Sara Meoni (S)

Nicolas Carriere (N)

Teodor Danaila (T)

Chloé Laurencin (C)

Stéphane Thobois (S)

Jean-Philippe Azulay (JP)

Frédérique Fluchere (F)

Mahmoud Charif (M)

Marie-Christine Picot (MC)

Lucie Hopes (L)

Anne-Gaelle Corbille (AG)

Tiphaine Rouaud (T)

Pascal Derkinderen (P)

Cosmin Alecu (C)

Charlotte Heraud (C)

Marie De Verdal (M)

Bertrand Degos (B)

Graziella Mangone (G)

Sara Sambin (S)

Aymeric Lanore (A)

Thomas Courtin (T)

Louise-Laure Mariani (LL)

David Bendetowicz (D)

Fouad Khoury (F)

Poornima Menon (P)

Florence Cormier-Dequaire (F)

Emmanuel Flamand-Roze (E)

David Grabli (D)

Elodie Hainque (E)

Marie Vidhaillet (M)

Aurélie Meneret (A)

Cécile Delorme (C)

Cendrine Foucard (C)

Florian Von Raison (F)

Alexis Elbaz (A)

Andreas Hartmann (A)

Vincent Leclercq (V)

Solène Ansquer (S)

Frederique Leh (F)

Marion Leclercq (M)

Guillaume Costentin (G)

None Lagha Boukbiza

Christine Brefel Courbon (C)

Clemence Leung (C)

Hélène Catala (H)

Astrid Causel (A)

Emilie Gaiffe (E)

Sandrine Dupouy (S)

Sandrine Villars (S)

Wei-Ho Lai (WH)

Rachida Bari (R)

Damien Chevanne (D)

Elodie Durand (E)

Isabelle Rieu (I)

Stephane Bernard (S)

Corinne Garsault (C)

Noel Boudjema (N)

Pascale Grebent (P)

Andrea Kistner (A)

Pierre Pelissier (P)

Valérie Santraine (V)

Thomas Gaudin (T)

Pierre Boutet (P)

Catherine Caire (C)

Manel Nouira (M)

Claudia Verna (C)

Amory Jardel (A)

Salomé Puisieux (S)

Guillemette Clement (G)

Lili Le Monnier (L)

Régis Frenais (R)

Séverine Le Dily (S)

Rachel Chaigneau (R)

Vanessa Ferrier (V)

Elodie David (E)

Leslie Fra (L)

Elsa Foucaran (E)

Carole Dongmo-Kenfack (C)

Florence Beauzor (F)

Mickael Le (M)

Sonia Messar (S)

Sophie Liot (S)

Emilie Rabois (E)

Margaux Bonnaire-Verdier (M)

Françoise Kestens (F)

Rozenn Gourhan (R)

Sandra Lopez-Alfaro (S)

Jean-François Houvenaghel (JF)

Mélanie Alexandre (M)

Christine Bourdonnais (C)

Linda Vernon (L)

Ahmed Boumediene (A)

Céline Julie (C)

Aurette Lobstein (A)

Nadine Longato (N)

Marie-Pierre Mitterle (MP)

Clélie Philips (C)

Hugo Rummel (H)

Stéphanie Bras (S)

Estelle Harroch (E)

Claudia Gillet (C)

Informations de copyright

Références

Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355(9):896–908. https://doi.org/10.1056/NEJMoa060281

doi: 10.1056/NEJMoa060281 pubmed: 16943402

Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson’s Disease: I. Invasive Therapies. Mov Disord 37(7):1360–1374. https://doi.org/10.1002/mds.29066

doi: 10.1002/mds.29066 pubmed: 35791767

Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson Pandemic. J Parkinsons Dis 8(s1):S3-s8. https://doi.org/10.3233/jpd-181474

doi: 10.3233/jpd-181474 pubmed: 30584159 pmcid: 6311367

Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R (2018) Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease. CNS Drugs 32(4):387–398. https://doi.org/10.1007/s40263-018-0498-4

doi: 10.1007/s40263-018-0498-4 pubmed: 29532440 pmcid: 5934466

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33(8):1248–1266. https://doi.org/10.1002/mds.27372

doi: 10.1002/mds.27372 pubmed: 29570866

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028. https://doi.org/10.1002/mds.20213

doi: 10.1002/mds.20213 pubmed: 15372591

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170. https://doi.org/10.1002/mds.22340

doi: 10.1002/mds.22340 pubmed: 19025984

Hauser RA, Walsh RR, Pahwa R, Chernick D, Formella AE (2021) Amantadine ER (Gocovri(®)) significantly increases ON time without any dyskinesia: pooled analyses from pivotal trials in Parkinson’s disease. Front Neurol 12:645706. https://doi.org/10.3389/fneur.2021.645706

doi: 10.3389/fneur.2021.645706 pubmed: 33841311 pmcid: 8032973

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181

doi: 10.1136/jnnp.55.3.181 pubmed: 1564476 pmcid: 1014720

Kaasinen V, Luo S, Martinez-Martin P, Goetz CG, Stebbins GT (2023) Cross-cultural differences in patient perceptions of dyskinesia in Parkinson’s disease. Mov Disord 38(4):688–692. https://doi.org/10.1002/mds.29335

doi: 10.1002/mds.29335 pubmed: 36670051

LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30(1):64–72. https://doi.org/10.1002/mds.26082

doi: 10.1002/mds.26082 pubmed: 25449210

Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE (2019) Parkinson’s disease in the Western Pacific Region. Lancet Neurol 18(9):865–879. https://doi.org/10.1016/s1474-4422(19)30195-4

doi: 10.1016/s1474-4422(19)30195-4 pubmed: 31175000

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B (2019) Descriptive analysis of the French NS-Park registry: towards a nation-wide Parkinson’s disease cohort? Parkinsonism Relat Disord 64:226–234. https://doi.org/10.1016/j.parkreldis.2019.04.012

doi: 10.1016/j.parkreldis.2019.04.012 pubmed: 31047798

Orayj K, Lane E (2019) Patterns and determinants of prescribing for Parkinson’s disease: a systematic literature review. Parkinson’s Dis. https://doi.org/10.1155/2019/9237181

doi: 10.1155/2019/9237181

Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82(4):300–307. https://doi.org/10.1212/wnl.0000000000000050

doi: 10.1212/wnl.0000000000000050 pubmed: 24371304

Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O’Brien MD, Silsbee H, Gronseth G, Lang AE (2021) Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a Report of the AAN Guideline Subcommittee. Neurology 97(20):942–957. https://doi.org/10.1212/wnl.0000000000012868

doi: 10.1212/wnl.0000000000012868 pubmed: 34782410 pmcid: 8672433

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S (2020) Utilization patterns of amantadine in Parkinson’s disease patients enrolled in the French COPARK Study. Drugs Aging 37(3):215–223. https://doi.org/10.1007/s40266-019-00740-2

doi: 10.1007/s40266-019-00740-2 pubmed: 31919803

Rascol O, Fabbri M, Poewe W (2021) Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol 20(12):1048–1056. https://doi.org/10.1016/s1474-4422(21)00249-0

doi: 10.1016/s1474-4422(21)00249-0 pubmed: 34678171

Rascol O, Ory-Magne F, Azulay JP, Defebvre L, Houeto JL, Maltete D, Remy P, Foubert-Samier A, Sommet A, Thalamas C, Thobois S, Corvol JC, Ns-Park/Fcrin N (2023) Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early parkinson disease (PD): the PREMANDYSK Trial. Mov Disord 38

Rosa MM, Ferreira JJ, Coelho M, Freire R, Sampaio C (2010) Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord 25(8):1053–1060. https://doi.org/10.1002/mds.23038

doi: 10.1002/mds.23038 pubmed: 20222132

Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404. https://doi.org/10.1002/ana.22029

doi: 10.1002/ana.22029 pubmed: 20687121

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/mds.23429

doi: 10.1002/mds.23429 pubmed: 21069833

Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology 50(5):1323–1326. https://doi.org/10.1212/wnl.50.5.1323

doi: 10.1212/wnl.50.5.1323 pubmed: 9595981

Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071. https://doi.org/10.1002/mds.25364

doi: 10.1002/mds.25364 pubmed: 23630119

Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963–968. https://doi.org/10.1002/ana.22164

doi: 10.1002/ana.22164 pubmed: 21154480

Zhang ZX, Chen H, Chen SD, Shao M, Sun SG, Qu QM, Zhang BR, Liu YM, Xu Q, Wan X, Li L, Wen HB, Chen X, Chen HB, Liu ZG, Wang J, Wang G (2014) Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes 7:65. https://doi.org/10.1186/1756-0500-7-65

doi: 10.1186/1756-0500-7-65 pubmed: 24476129 pmcid: 3928922